How do behavioral symptoms of dementia commonly present?

Behavioral symptoms can include anxiety, depression, and psychosis such as imagining things that aren't there or delusions. These can be the presenting feature of dementia in some people and are frequent reasons for hospitalization. (Timestamp: 330)

Are dementia patients aware of their cognitive decline in the early stages?

Patient awareness varies greatly. Some are blissfully unaware throughout, while others are acutely aware that something is wrong, even before discernible changes appear on testing. Those with awareness often suffer the most. (Timestamp: 539)

What is the clinical definition and diagnostic process for dementia?

Dementia is an umbrella term for changes in memory and cognition that interfere with daily function, representing a change from a person's previous state. Diagnosis relies on a thorough clinical interview with the patient and an observer, cognitive testing, brain imaging (like MRI and FDG PET), and lab tests to rule out reversible causes. (Timestamp: 700)

How do you distinguish normal age-related forgetfulness from early dementia?

Memory issues must be evaluated in context. Normal aging, stress, and poor sleep can cause forgetfulness. Dementia is suspected when memory problems are frequent, intense, and represent a significant change from an individual's normal functioning, rather than just an occasional lapse. (Timestamp: 1210)

Is amyloid necessary for an Alzheimer's diagnosis?

Pathologically, amyloid plaques and tau tangles are required for an Alzheimer's diagnosis. However, amyloid can build up in the brain 10-20 years before symptoms appear. It is necessary for Alzheimer's disease, but not for all types of dementia. (Timestamp: 1578)

What is Lewy Body Dementia and how is it different from Alzheimer's?

Lewy Body Dementia presents as a triad of fluctuating cognitive impairment (Alzheimer's-like), parkinsonism (stiffness, shuffling gait), and prominent visual hallucinations. Unlike classic Alzheimer's, which typically starts with short-term memory loss and a slower decline, Lewy Body Dementia often has a more precipitous decline over 8-10 years. (Timestamp: 2887)

How has the approach to Alzheimer's evolved in clinical practice over the last 20 years?

There's increased public awareness that Alzheimer's is a disease, not a normal part of aging, and that early intervention matters. More people now seek baseline evaluations, prevention tips, and get involved in research, understanding that early medication can slow decline and preserve function longer. (Timestamp: 3554)

What kind of behavioral medications are typically prescribed for dementia patients?

SSRIs (selective serotonin reuptake inhibitors) are frequently prescribed for anxiety and depression due to good tolerability and low fall risk. Benzodiazepines are generally avoided due to increased confusion and hip fracture risk. (Timestamp: 3853)

How do caregivers cope with a loved one's dementia diagnosis?

Caregivers often experience a form of grief for someone still alive, progressing through denial and anger. They benefit from support and education, learning tools to handle behaviors, and understanding that problematic actions are disease-driven, not intentional. (Timestamp: 4038)

What are the three main categories of drugs in the Alzheimer's clinical trial pipeline?

The three categories are cognitive enhancement (symptomatic), neuropsychiatric and behavioral improvement (symptomatic), and disease modification. Currently, symptomatic treatments are approved, but 80% of the pipeline focuses on disease-modifying treatments. (Timestamp: 4906)

Why have many early Alzheimer's disease-modifying drug trials failed?

Early disease-modifying drug trials often failed because they targeted amyloid too late in the disease progression (mild to moderate dementia). By this stage, too much neurodegeneration had already occurred, making amyloid removal ineffective. Current trials focus on earlier stages like mild cognitive impairment or preclinical Alzheimer's. (Timestamp: 5388)

What is the significance of the upcoming FDA decision on Aducanumab from Biogen?

The FDA's decision on Aducanumab is highly anticipated as it could be the first disease-modifying treatment for Alzheimer's in nearly 20 years. There's significant advocacy for approval due to the lack of new options, despite mixed data interpretation from advisory panels. (Timestamp: 6540)

What are the key components of healthy aging, according to a geriatric psychiatrist?

Healthy aging is less about avoiding decline and more about attitude, focusing on what you can still do, and maintaining quality relationships. Letting go of regrets, not dwelling on losses, and living in the present are crucial for emotional well-being and successful aging, even with illness. (Timestamp: 7009)

Can exercise help improve cognitive function for people with dementia?

Yes, a growing body of data indicates that aerobic activity can improve scores on cognitive testing even in people who already have cognitive impairment or full-blown dementia. (Timestamp: 7675)

Key Moments

164 - Diagnosing, preventing, & treating Alzheimer’s disease, & life lessons from dementia patients

Peter Attia MD

People & Blogs4 min read132 min video

Jun 7, 2021|22,456 views|481|66

Save to Pod

Key Moments

TL;DR

Alzheimer's diagnosis, treatment, ApoE, and life lessons from dementia patients.

Key Insights

Dementia is an umbrella term; Alzheimer's is the most common cause, diagnosed via clinical interview, cognitive testing, and brain imaging.

Early recognition of dementia symptoms is crucial, as awareness in the early stages can cause significant suffering for patients.

Vascular disease and amyloid buildup are key factors in dementia, often co-occurring with Alzheimer's, highlighting the importance of managing cardiovascular risk.

Research is advancing towards drug development targeting the underlying pathology of Alzheimer's, moving beyond symptomatic treatments.

Life lessons from dementia patients emphasize the importance of living in the present moment, focusing on relationships, and adapting to changes.

Even with cognitive impairment, aerobic exercise can improve cognitive test scores, underscoring its role in brain health.

THE PATH TO GERIATRIC PSYCHIATRY AND DIAGNOSING DEMENTIA

Dr. Amanda Grant Smith's passion for geriatric psychiatry stemmed from witnessing ageism in medicine and the profound impact of dementia on patients and families. Dementia, an umbrella term for cognitive changes interfering with daily function, is often misdiagnosed, with early symptoms potentially presenting as psychosis or behavioral changes that mimic other psychiatric conditions. The diagnostic process relies heavily on a comprehensive clinical interview with both the patient and an observer, cognitive testing, and brain imaging to rule out other causes and identify patterns suggestive of specific dementias.

DIFFERENTIATING DEMENTIA TYPES AND THE ROLE OF BIOMARKERS

Distinguishing between various forms of dementia, such as Alzheimer's disease and Lewy body dementia, involves careful clinical assessment. Alzheimer's typically begins with short-term memory loss, while Lewy body dementia presents with a triad of cognitive impairment, parkinsonism, and visual hallucinations, often with fluctuating severity. While amyloid PET scans and CSF analysis are valuable research tools for confirming Alzheimer's pathology, their cost and accessibility limit routine clinical use. MRI imaging plays a role in identifying vascular disease and hippocampal atrophy, which can be biomarkers for Alzheimer's.

THE SCIENCE BEHIND ALZHEIMER'S: AMYLOID, TAU, AND VASCULAR FACTORS

The pathological hallmarks of Alzheimer's disease are amyloid plaques and tau tangles, with amyloid buildup often beginning 10-20 years before symptom onset. Emerging research suggests tau may play a more direct role in staging cognitive decline. The interplay between amyloid, tau, and cerebrovascular health is complex. Managing cardiovascular risk factors is crucial, as vascular disease frequently co-occurs with Alzheimer's, contributing to mixed dementia. Understanding these underlying pathologies is key to developing effective disease-modifying treatments.

CLINICAL TRIALS AND THE EVOLVING TREATMENT LANDSCAPE

The drug development pipeline for Alzheimer's disease has historically been challenging, but a significant shift towards disease-modifying therapies targeting amyloid and tau is underway. While symptomatic treatments like cholinesterase inhibitors and NMDA receptor antagonists help manage cognitive and behavioral symptoms, they do not alter the disease progression. The focus is now on early intervention, with trials exploring prevention in preclinical stages and treatment of mild cognitive impairment (MCI). The development of accessible blood biomarkers for diagnosis and risk assessment is also a promising area.

MANAGING BEHAVIORAL AND PSYCHIATRIC SYMPTOMS

Behavioral and psychiatric symptoms, including anxiety, depression, and psychosis, are common in dementia and significantly impact quality of life for both patients and caregivers. While these symptoms can be challenging, they are treatable. Antidepressants, particularly SSRIs, are frequently prescribed for their efficacy in managing anxiety and depression, with careful consideration for age, renal function, and potential drug interactions. Avoiding benzodiazepines is often recommended due to risks of increased confusion and falls. Treatment focuses on the safest, lowest effective dose for the shortest necessary duration.

LIVING WELL WITH DEMENTIA: ADAPTATION AND LIFE LESSONS

Healthy aging involves adapting to inevitable physical and cognitive changes by focusing on emotional well-being and relationships. Individuals who age successfully, even with illness, tend to focus on what they can still do rather than what they have lost. They embrace the present moment, finding joy in simple pleasures and maintaining strong social connections. Caregivers often benefit from education and support, learning to reframe challenging behaviors and manage their own emotional well-being, recognizing that the process of adjustment often involves stages of grief and acceptance.

THE IMPORTANCE OF INTERVENTION: PREVENTION AND HEALTHY AGING

While the ideal approach to combating cognitive decline is prevention, interventions remain crucial for those already experiencing symptoms. This includes managing modifiable risk factors like hypertension, diabetes, and dyslipidemia, which benefit both cardiovascular and brain health. Even for individuals with diagnosed cognitive impairment or dementia, regular aerobic exercise has shown potential to improve cognitive test scores. Ultimately, fostering emotional resilience through quality relationships and embracing a philosophy of living in the moment can significantly enhance overall well-being, regardless of age or health status.

Mentioned in This Episode

●Software & Apps

●Companies

●Organizations

●Concepts

●People Referenced

Common Questions

Geriatric psychiatry focuses on mental health in older adults. It's crucial for Alzheimer's as it addresses significant behavioral and mood changes (like anxiety, depression, psychosis) that often accompany cognitive decline, improving quality of life for both patients and caregivers. (Timestamp: 77)

Topics

Alzheimer'S Disease Health & Longevity Neuroscience & the Brain Mindset & Self-Improvement Aerobic Exercise Cognitive Decline Healthy Aging Clinical Trials Medicine & Clinical Dementia Diagnosis Geriatric Psychiatry Mental Health In Aging

Mentioned in this video

Drugs & Medications

Donepezil

One of the first FDA-approved treatments for Alzheimer's, approved in 1997, which the guest witnessed the evolution of. It's a cholinesterase inhibitor that slows down cognitive decline.

Donanemab

A Lilly study drug, an anti-amyloid monoclonal antibody, that recently showed it met primary and secondary endpoints at the ADPD meeting, offering another promising development in Alzheimer's treatment.

SSRIs

A class of antidepressants frequently prescribed for anxiety and depression in dementia patients due to their effectiveness and good tolerability, generally not increasing fall risk.

Aducanumab

A monoclonal antibody against amyloid developed by Biogen, which underwent two parallel Phase 3 trials (EMERGE and ENGAGE) with mixed results but ultimately showed promise in high-dose groups. Its FDA approval decision is highly anticipated.

Concepts

Frontotemporal Dementia

A type of dementia that often presents with relatively preserved memory but significant changes in language or behavior, sometimes misdiagnosed as bipolar illness due to profound behavior changes.

Tau

A protein that forms tangles in the brain in Alzheimer's disease and other dementias, with its spread correlating more to symptoms than amyloid.

Hippocampal Atrophy

Shrinking in the hippocampus, a brain region crucial for short-term memory, which can be a biomarker of Alzheimer's disease, though it can also be influenced by other factors like stress.

Lewy Body dementia

A type of dementia with features of both Alzheimer's and Parkinson's disease, characterized by prominent visual hallucinations and fluctuating cognitive and motor symptoms. It tends to have a quicker decline than Alzheimer's.

APOE4 gene

A genotype that carries a higher risk for Alzheimer's disease, particularly for homozygotes, and can influence responses to cardiovascular medications. It's not diagnostic but indicates risk.

Amyloid-Related Imaging Abnormalities

Side effects seen with amyloid-removing drugs, presenting as edema (ARIA-E) or microhemorrhages (ARIA-H) on MRI. Risk is higher in APOE4 carriers.

People

Dennis Dickson

A researcher at Mayo Clinic Jacksonville whose autopsy studies show that most neuropathology in dementia is mixed, not pure Alzheimer's.

Lauren Miller Rogen

A previous podcast guest and patient of the geriatric psychiatrist, who shared a compelling journey through the stages of grief related to her mother's dementia.

Richard Isaacson

A neurologist and Alzheimer's expert who runs a prevention clinic at Cornell. He was part of a previous discussion with the host and guest.

Francesco Gonzalez-Lima

A researcher at UT Austin who believes microvascular disease is a significant driver of cognitive impairment.

Eric Pfeiffer

Founder of the Suncoast Gerontology Center in 1980 and a leader in geriatric psychiatry and Alzheimer's disease, who mentored the guest.

Elizabeth Kubler-Ross

Known for her five stages of grief, a model used to understand how patients and caregivers process diagnoses like cancer and Alzheimer's.

Laura Baker

A researcher at Wake Forest who is doing significant work on the benefits of aerobic exercise for cognitive improvement, even in people with dementia.

Supplements

Benzodiazepines

A class of drugs (e.g., alprazolam, lorazepam, diazepam) that are generally avoided in older adults with dementia due to their potential to increase confusion and significantly raise the risk of hip fracture with chronic use.

Companies

Eli Lilly and Company

The pharmaceutical company behind the Donanemab study which showed promising results for Alzheimer's treatment.

Biogen

A pharmaceutical company that manufactures Aducanumab, a highly discussed monoclonal antibody targeting amyloid for Alzheimer's treatment.

Organizations

Bryn Mawr Hospital

The hospital where the guest had an enlightening experience with an elderly patient, realizing the quickness people are to brush off the elderly.

Hilarity for Charity

An organization that hosts events to raise awareness and funds for Alzheimer's disease.

Studies & Research

amyloid beta

A protein fragment that accumulates in the brain, forming plaques in Alzheimer's disease. Its buildup can start 10-20 years before symptoms.

Software & Apps

FDG PET scan

A type of PET scan that measures how well the brain is using glucose as fuel, showing different patterns that support various dementia diagnoses.

CDR

A primary endpoint measure for Alzheimer's drug trials, which involves a subjective interview and rating based on patient and informant reports across six dimensions (e.g., memory, judgment, hobbies).